Stocks · News reference
BMO Capital analyst John McNulty maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $26 to $18.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Chemours (NYSE:CC) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $18 to $16.
Chemours PFAS settlement lifts shares as the $455 million deal clarifies liabilities, payment timing and future escrow obligations.